Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro

  • Authors:
    • Shun‑Yao Ko
    • Hshin‑An Ko
    • Tzong‑Ming Shieh
    • Tzong‑Cherng Chi
    • Hong‑I Chen
    • Yi‑Ting Chen
    • Ya‑Hui Yu
    • Shu‑Han Yang
    • Shu‑Shing Chang
  • View Affiliations

  • Published online on: March 6, 2017     https://doi.org/10.3892/ol.2017.5809
  • Pages: 3328-3334
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

An irreversible non-enzymatic reaction between carbohydrates and proteins results in the formation of advanced glycation end products (AGEs). AGEs have been demonstrated to be a risk factor of complications in patients with diabetes mellitus (DM). Previous studies have suggested that patients with DM exhibit a higher rate of metastasis of oral cancer and a lower cancer‑associated survival rate. The receptor for AGEs (RAGE) has been associated with angiogenesis and an increase in cancer malignancy. Previous studies have suggested that AGE‑RAGE regulates cell migration via extracellular signal‑regulated kinase (ERK) phosphorylation. Nuclear factor-erythroid 2-related factor 2 (Nrf-2) is associated with the regulation of tumor protein p53 (p53) and the apoptotic response of oral cancer cells. AGEs are associated with oral cancer; however, the mechanism underlying this association remains to be elucidated. The present study hypothesized that AGEs regulate Nrf‑2 and downstream pathways through ERK phosphorylation. The results of the current study demonstrated that AGEs inhibit the expression of Nrf‑2, p53 and Bcl‑2 associated x apoptosis regulator, and increase the expression of apoptosis regulator Bcl‑x protein. The effect of AGEs was inhibited through the use of the PD98059. The present study demonstrated that AGEs regulate the downstream pathways Nrf-2 and Bcl-xl via ERK phosphorylation. It is suggested that AGEs regulate the survival of oral cancer cells via Nrf‑2 and Bcl‑xl through p53 regulation, which explains the poor prognosis of patients with DM who have oral cancer.

Introduction

An irreversible non-enzymatic reaction between carbohydrates and proteins produce advanced glycation end products (AGEs) (1,2). The accumulation of AGEs increases with age (3,4) and is typically higher in patients with diabetes mellitus (DM) (5). AGEs have been revealed to be a risk factor for complications of DM (69) and an important toxicity moiety for neuronal cells in Alzheimer's disease (1013). Previous studies have demonstrated that cancer malignancy can be promoted by AGEs (1416). Furthermore, the migration of oral cancer cells has been revealed to be increased by the receptor for AGEs (17). In a clinical setting, patients with DM exhibit a higher rate of metastasis of oral cancer and a lower cancer-associated survival rate (18). A strong association appears to exist between AGEs and oral cancer; however, the underlying mechanism of the involvement of AGEs in oral cancer remains to be elucidated.

Antioxidant responsive element is regulated by nuclear factor-erythroid 2-related factor 2 (Nrf-2), which in turn regulates the expression of antioxidant genes (1922). Reactive oxygen species degradation (23,24), anti-inflammatory responses (2528), and neuroprotection (29) are regulated by Nrf-2 through the downstream antioxidant genes heme oxygenase 1 (HO-1) and NAD(P)H dehydrogenase quinone 1 (3033). In addition, Nrf-2 regulates the apoptotic response via tumor protein p53 regulation (34). Furthermore, in oral cancer cells, Nrf-2 and HO-1 upregulation appear to be associated with apoptosis (35).

A previous study by our group demonstrated that AGEs regulate cell migration via extracellular signal-regulated kinase (ERK) phosphorylation (17). Therefore, it was hypothesized that AGEs regulate Nrf-2 and downstream signaling pathways through ERK phosphorylation. The expression of various apoptosis-associated proteins, including Nrf-2, HO-1, p53, Bcl-2 associated × apoptosis regulator (Bax) and apoptosis regulator Bcl-x (Bcl-xl), in SAS oral cancer cells following treatment with AGEs was analyzed through western blot analysis, in order to investigate the role and underlying mechanism of AGEs in oral cancer.

Materials and methods

Reagents

Phenylmethylsulfonyl fluoride, bovine serum albumin (BSA), DL-glyceraldehyde, resveratrol and PD98059 were purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin and Hank's Balanced Salt Solution were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). GAPDH was purchased from Chemicon International, Inc. (Temecula, CA, USA). ERK, phosphorylated (p)-ERK, Nrf-2, HO-1, p53, Bax and Bcl-xl were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Nitrocellulose membranes were purchased from Pall Corporation (Port Washington, NY, USA). The enhanced chemiluminescence (ECL) Immobilon western chemiluminescent HRP substrate kit was purchased from EMD Millipore (Billerica, MA, USA).

Preparation of AGEs

AGEs were prepared by incubation with BSA (pH 7.4) in PBS with 20 mM DL-glyceraldehyde at 37°C for 1 week. The product was dialyzed using dialysis membranes (cat. no. MWCO 6000; Orange Scientific, Braine-l'Alleud, Belgium) in PBS at 4°C for 2 h, and the cycle was repeated five times. The product was then concentrated at 4°C using Amicon Ultra-15 centrifugal filter units (EMD Millipore) and centrifuged at 830 × g for 30 min prior to storage at −80°C as described in a previous study (36).

Cell culture and treatment

The oral cancer cell line SAS (Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan) was cultured in an atmosphere of 5% CO2 at 37°C. The culture was maintained in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS, 100 U/ml penicillin, 2 mM L-glutamine and 100 µg/ml streptomycin. Cells were cultured in serum-free DMEM for 24 h prior to treatment.

Western blot analysis

Total protein (30 µg) was resolved using SDS-PAGE on a 10% gel and transferred to nitrocellulose membranes (Pall Corporation). The membranes were blocked using non-fat milk and incubated overnight at 4°C with primary antibodies directed against the following proteins: p-ERK, ERK, Nrf-2, HO-1, p53, Bax, Bcl-xl (all dilution, 1:1,000) and GAPDH (dilution, 1:40,000). Primary antibodies were removed and the membranes were washed using PBS with Tween-20 (PBST) buffer three times for 30 min at room temperature. The membranes were subsequently incubated for 45 min at room temperature with the following secondary antibodies: Horseradish peroxidase-conjugated anti-mouse (cat. no. AP124P; Chemicon International, Inc.), anti-rabbit (cat. no. AP132P; Merck Millipore) and anti-goat (cat. no. 605-4313; Rockland Immunochemicals Inc., Limerick, PA, USA) (all dilutions, 1:4,000). The secondary antibodies were removed and the membranes were washed using PBST buffer twice for 30 min. Protein bands were detected using Millipore ECL. The density of the protein bands was quantified using Image J software version 1.4 (National Institutes of Health, Bethesda, MA, USA) following normalization with GAPDH. All data are presented as the mean ± standard deviation from experiments performed in triplicate.

Statistical analysis

Student's t-tests were conducted using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Pathways associated with apoptosis are regulated by resveratrol

SAS cells were treated with resveratrol (1.25 and 2.5 µM) for 24 h, and Nrf-2, HO-1, p53 and Bax protein expression was detected using western blot analysis. The results demonstrated that, compared with the untreated control group, resveratrol significantly increased Nrf-2 (1.25 µM, 1.42±0.06, P=0.002; 2.5 µM, 1.35±0.1, P=0.03), HO-1 (1.25 µM, 1.24±0.04, P=0.003; 2.5 µM, 1.37±0.11, P=0.03), p53 (1.25 µM, 1.32±0.1, P=0.04; 2.5 µM, 1.79±0.24, P=0.03) and Bax (2.5 µM, 1.49±0.03, P<0.0001) expression (Fig. 1).

Regulation of apoptosis-associated pathways by AGEs

SAS cells were treated with AGEs (200 and 400 µg/ml) or BSA (400 µg/ml; negative control) for 24 h. Western blot analysis was used to detect Nrf-2, HO-1, p53 and Bax protein expression. The results revealed that compared with the untreated control group, treatment with 400 µg/ml AGEs significantly decreased Nrf-2 (0.64±0.05; P=0.002), p53 (0.72±0.06; P=0.008) and Bax (0.7±0.03; P=0.0005) expression (Fig. 2).

AGEs regulation of apoptosis-associated signaling pathways via ERK phosphorylation

Following the treatment of SAS cells with AGEs or BSA for 24 h, Bcl-xl and p-ERK were detected using western blot analysis. Treatment with AGEs was associated with a significant increase in Bcl-xl (200 µg/ml, 1.23±0.07, P=0.03; 400 µg/ml, 1.36±0.04; P=0.0006; Fig. 3A) and ERK phosphorylation (200 µg/ml, 1.2±0.01, P<0.00001; 400 µg/ml, 1.26±0.02, P=0.0004; Fig. 3B) compared with the untreated control groups. However, treatment with 400 µg/ml BSA also significantly increased p-ERK compared with the control group (1.25±0.04; P=0.003; Fig. 3B). A pretreatment of 10 µM PD98059 for 1 h was used on the cells to inhibit the phosphorylation of ERK (Fig. 4A). Pretreatment with PD98059 blocked the effect of AGEs on HO-1, Bcl-xl and Bax expression (Fig. 4B). Furthermore, compared with the untreated control group, pretreatment with PD98059 prior to treatment with AGEs significantly increased the expression of Nrf-2 (200 µg/ml, 1.27±0.04, P=0.003; 400 µg/ml, 1.24±0.03, P=0.001) and p53 (200 µg/ml, 1.43±0.06, P=0.002; 400 µg/ml, 1.39±0.08, P=0.01) (Fig. 4B). The mechanism by which AGEs were observed to influence the survival rate of oral cancer cells in the present study is presented in Fig. 5.

Discussion

An association has been demonstrated between oral cancer and DM (3739); however, the mechanism underlying this association remains to be elucidated. A previous study by our group revealed that AGEs regulate oral cancer cell migration via the ERK signaling pathway (17). The results demonstrated the mechanism by which AGEs regulate p53 via ERK and downstream Nrf-2 and Bcl-xl. To the best of our knowledge, this is the first study to elucidate the mechanism of action of AGEs in oral cancer cells.

Previous studies have demonstrated the antitumorigenic effects of resveratrol (4042). In oral cancer, resveratrol suppresses cell growth, DNA synthesis, migration and invasion, and increases cell apoptosis (4345). A previous study reported that Nrf-2 regulates the p53 signaling pathway, leading to an apoptotic response (34). A study by Lee et al (35) suggested that the apoptosis of oral cancer cells is regulated by Nrf-2 and downstream HO-1 and p53. These results support the contention that Nrf-2 enhances cell apoptosis via the p53 signaling pathway. The results of the present study demonstrated that resveratrol significantly increased Nrf-2, HO-1, p53 and Bax protein expression, suggesting that resveratrol induces apoptosis through Nrf-2, HO-1, p53 and Bax signaling pathways. The results of the current study demonstrated that, in contrast to resveratrol, AGEs significantly decrease Nrf-2, HO-1, p53 and Bax, and increase Bcl-xl protein expression. This indicates that AGEs modulate oral cancer survival via regulation of the expression of Nrf-2 and Bcl-xl.

In the present study, ERK phosphorylation was significantly upregulated by AGEs and the pretreatment of SAS cells with PD98059 to suppress ERK activation inhibited the effects of AGEs on p-ERK, HO-1, Bcl-xl and Bax expression, whereas Nrf-2 and p53 expression significantly increased. Treatment with AGEs significantly increased Bcl-xl, and decreased p53 protein expression. A previous study by Chipuk et al (46) suggested that an interaction between Bcl-xl and p53 inhibits the activation of Bax. Li et al (47) reported that Bcl-xl inhibits p53 resulting in an anti-apoptotic effect. These results suggest that AGEs regulate p53 via ERK phosphorylation to inhibit Nrf-2 and activate Bcl-xl. In addition, AGEs and BSA increased ERK phosphorylation in the current study. However, AGEs decreased Nrf-2 and p53 protein expression. The pretreatment of SAS cells with PD98059 increased Nrf-2 and p53 expression. The results of the present study suggest that treatment with AGEs or BSA differ regarding their effects on oral cancer cells (17).

The results of the current study suggest that AGEs decrease Nrf-2 and p53 expression and increase Bcl-xl expression via ERK phosphorylation. To the best of our knowledge, this is the first study to demonstrate that AGEs regulate the expression of Nrf-2 and Bcl-xl, which subsequently influences p53 expression via ERK phosphorylation. In conclusion, the results of the present study suggest a mechanism by which AGEs influence the survival rate of oral cancer cells. This mechanism involves AGEs increasing ERK phosphorylation, which stimulates downstream Nrf-2 inhibition and Bcl-xl upregulation. This subsequently suppresses p53 and Bax expression, the effects of which manifest as a change in the survival rate of oral cancer cells. These findings explain the increase in oral cancer invasiveness and decrease in the survival rate of patients with DM, who typically have higher levels of AGEs. In addition, the results of the current study indicate that the accumulation of AGEs due to aging or DM promotes the progression of oral cancer.

Acknowledgements

The present study was supported by the National Science Council of Taiwan (grant no. 100-2314-B-309-002-MY3).

Glossary

Abbreviation

Abbreviations:

AGEs

advanced glycation end products

References

1 

Kasper M and Funk RH: Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr. 32:233–243. 2001. View Article : Google Scholar : PubMed/NCBI

2 

Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF and Schmidt AM: Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 15:16R–28R. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Luth HJ, Ogunlade V, Kuhla B, Kientsch-Engel R, Stahl P, Webster J, Arendt T and Münch G: Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex. 15:211–220. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Munch G, Thome J, Foley P, Schinzel R and Riederer P: Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev. 23:134–143. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Thorpe SR and Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 9:69–77. 1996. View Article : Google Scholar : PubMed/NCBI

6 

Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 1498:99–111. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S and Takeuchi M: TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med. 6:351–358. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Basta G, Schmidt AM and De Caterina R: Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 63:582–592. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Thornalley PJ: Glycation free adduct accumulation in renal disease: The new AGE. Pediatr Nephrol. 20:1515–1522. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R and Yamagishi S: Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res. 1:39–46. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S and Takeuchi M: Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 21:197–208. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y and Makita Z: Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol. 59:1094–1105. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S and Saito T: Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol. 108:189–193. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Bhawal UK, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T, Nomura Y, Sato F, Fujimoto K, Sasaki N, Ikeda MA, et al: Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology. 69:246–255. 2005. View Article : Google Scholar : PubMed/NCBI

15 

Cai Q, Li BY, Gao HQ, Zhang JH, Wang JF, Yu F, Yin M and Zhang Z: Grape seed procyanidin b2 inhibits human aortic smooth muscle cell proliferation and migration induced by advanced glycation end products. Biosci Biotechnol Biochem. 75:1692–1697. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Takino J, Yamagishi S and Takeuchi M: Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol. 2010:7398522010. View Article : Google Scholar : PubMed/NCBI

17 

Ko SY, Ko HA, Shieh TM, Chang WC, Chen HI, Chang SS and Lin IH: Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One. 9:e1105422014. View Article : Google Scholar : PubMed/NCBI

18 

Wu CH, Wu TY, Li CC, Lui MT, Chang KW and Kao SY: Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma: A retrospective cohort study. Ann Surg Oncol. 17:2175–2183. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Motohashi H, Katsuoka F, Engel JD and Yamamoto M: Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci USA. 101:6379–6384. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem. 275:16023–16029. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Ishii T, Itoh K and Yamamoto M: Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol. 348:182–190. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI

23 

Hsieh CY, Hsiao HY, Wu WY, Liu CA, Tsai YC, Chao YJ, Wang DL and Hsieh HJ: Regulation of shear-induced nuclear translocation of the Nrf2 transcription factor in endothelial cells. J Biomed Sci. 16:122009. View Article : Google Scholar : PubMed/NCBI

24 

Mann GE, Rowlands DJ, Li FY, de Winter P and Siow RC: Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res. 75:261–274. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Itoh K, Mochizuki M, Ishii Y, Ishii T, Shibata T, Kawamoto Y, Kelly V, Sekizawa K, Uchida K and Yamamoto M: Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol. 24:36–45. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH and Kunsch C: Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol. 290:H1862–H1870. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Mochizuki M, Ishii Y, Itoh K, Iizuka T, Morishima Y, Kimura T, Kiwamoto T, Matsuno Y, Hegab AE, Nomura A, et al: Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am J Respir Crit Care Med. 171:1260–1266. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Harada N, Kanayama M, Maruyama A, Yoshida A, Tazumi K, Hosoya T, Mimura J, Toki T, Maher JM, Yamamoto M and Itoh K: Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. Arch Biochem Biophys. 508:101–109. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Bell KF, Al-Mubarak B, Fowler JH, Baxter PS, Gupta K, Tsujita T, Chowdhry S, Patani R, Chandran S, Horsburgh K, et al: Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci USA. 108:E1–E2; author reply E3-4. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Riley RJ and Workman P: DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 43:1657–1669. 1992. View Article : Google Scholar : PubMed/NCBI

31 

Clark JE, Foresti R, Green CJ and Motterlini R: Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem J 348 Pt. 3:615–619. 2000. View Article : Google Scholar

32 

Jyrkkanen HK, Kansanen E, Inkala M, Kivelä AM, Hurttila H, Heinonen SE, Goldsteins G, Jauhiainen S, Tiainen S, Makkonen H, et al: Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res. 103:e1–e9. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Nioi P, McMahon M, Itoh K, Yamamoto M and Hayes JD: Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H: Quinone oxidoreductase 1 gene: Reassessment of the ARE consensus sequence. Biochem J. 374:337–348. 2003. View Article : Google Scholar : PubMed/NCBI

34 

You A, Nam CW, Wakabayashi N, Yamamoto M, Kensler TW and Kwak MK: Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2. Arch Biochem Biophys. 507:356–364. 2011. View Article : Google Scholar : PubMed/NCBI

35 

Lee YM, Auh QS, Lee DW, Kim JY, Jung HJ, Lee SH and Kim EC: Involvement of Nrf2-mediated upregulation of heme oxygenase-1 in mollugin-induced growth inhibition and apoptosis in human oral cancer cells. Biomed Res Int. 2013:2106042013.PubMed/NCBI

36 

Ko SY, Lin YP, Lin YS and Chang SS: Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med. 49:474–480. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Vairaktaris E, Spyridonidou S, Goutzanis L, Vylliotis A, Lazaris A, Donta I, Perrea D, Yapijakis C and Patsouris E: Diabetes and oral oncogenesis. Anticancer Res. 27:4185–4193. 2007.PubMed/NCBI

38 

Girtan M, Zurac S, Stăniceanu F, Bastian A, Popp C, Nichita L, Laba E and Forna N: Oral epithelial hyperplasia in diabetes mellitus. Rom J Intern Med. 47:201–203. 2009.PubMed/NCBI

39 

Vairaktaris E, Kalokerinos G, Goutzanis L, Yapijakis C, Derka S, Vassiliou S, Spyridonidou S, Vylliotis A, Nkenke E, Lazaris A and Patsouris E: Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis. Int J Oral Maxillofac Surg. 37:60–65. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Ulrich S, Loitsch SM, Rau O, von Knethen A, Brüne B, Schubert-Zsilavecz M and Stein JM: Peroxisome proliferator-activated receptor gamma as a molecular target of reveratrol-induced modulation of polyamine metabolism. Cancer Res. 66:7348–7354. 2006. View Article : Google Scholar : PubMed/NCBI

41 

Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N and Merli F: Resveratrolmediated apoptosis of hodgkin lymphoma cells invovles SIRT1 inhibition and FOXO3a hyperacetylation. Int J Cancer. 132:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Yang Q, Wang B, Zang W, Wang X, Liu Z, Li W and Jia J: Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One. 8:e706272013. View Article : Google Scholar : PubMed/NCBI

43 

Elattar TM and Virji AS: The effect of red wine and its components on growth and proliferation of human oral squamous carcinoma cells. Anticancer Res. 19:5407–5414. 1999.PubMed/NCBI

44 

Shan Z, Yang G, Xiang W, Pei-jun W and Bin Z: Effects of resveratrol on oral squamous cell carcinoma (OSCC) cells in vitro. J Cancer Res Clin Oncol. 140:371–374. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Kim SH, Kim HJ, Lee MH, Yu SK, Kim CS, Kook JK, Chun HS, Park E, Lee SY, Kim SG, et al: Resveratrol induces apoptosis of KB human oral cancer cells. J Korean Soc Appl Biol Chem. 54:966–971. 2011. View Article : Google Scholar

46 

Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI

47 

Li G, Xie N, Yao Y, Zhang Y, Guo J, Feng Y, Lv F, Xiao RP and Cao CM: Identification of PI3K regulatory subunit p55γ as a novel inhibitor of vascular smooth muscle cell proliferation and neointimal formation. Cardiovasc Res. 105:75–85. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ko SY, Ko HA, Shieh TM, Chi TC, Chen HI, Chen YT, Yu YH, Yang SH and Chang SS: Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett 13: 3328-3334, 2017
APA
Ko, S., Ko, H., Shieh, T., Chi, T., Chen, H., Chen, Y. ... Chang, S. (2017). Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncology Letters, 13, 3328-3334. https://doi.org/10.3892/ol.2017.5809
MLA
Ko, S., Ko, H., Shieh, T., Chi, T., Chen, H., Chen, Y., Yu, Y., Yang, S., Chang, S."Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro". Oncology Letters 13.5 (2017): 3328-3334.
Chicago
Ko, S., Ko, H., Shieh, T., Chi, T., Chen, H., Chen, Y., Yu, Y., Yang, S., Chang, S."Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro". Oncology Letters 13, no. 5 (2017): 3328-3334. https://doi.org/10.3892/ol.2017.5809